Christine (C. W.) Bruggeman
Molecular Life Sciences, Immunology
The aim of my project is to study the immunomodulatory working mechanisms of intravenous immunoglobulin (IVIg) in order to further optimize and enhance the efficacy of IgG-based therapies.
IVIg is a polyclonal IgG preparation, pooled from the plasma from more than 10,000 individuals. It is used for the treatment of a wide variety of diseases. Firstly, IVIg is used in patients lacking IgG to treat infection. Secondly, IVIg is used as an immunomodulatory agent for specific autoinflammatory diseases, like Idiopathic Trombocytopenic Purpura (ITP), Kawasaki Disease (KD) and autoinflammatory neurological diseases. The exact working mechanism of IVIg in these inflammatory conditions is unknown, but in recent years it has become clear that the affinity of IgG for IgG receptors (FcγR), and hence the functional activity of IgG, is affected by the nature of Fc glycosylation. The aim of my project is to dissect the basis for the immunomodulatory effects of IVIg, with a specific focus on the contribution of glycosylation and the role(s) of FcγR expressed on immune cells.
- Flow cytometry
- Phagocytosis assays
- Cell culture
- Blood cell isolation
|2014-present||PhD student at the Dept of Blood Cell Research, Sanquin Research, Amsterdam|
|2013||Intern at the Molecular Immunology department, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia|
|2012||Intern at the Cell Biology and Immunology department, Wageningen University|
|2011-2014||MSc Molecular Life Sciences, Wageningen University. Specialization: Biomedical Research|
|2008-2011||BSc Molecular Life Sciences, Wageningen University|